Abstract
Obesity and type 2 diabetes continue to be major public health burdens with type 2 diabetes rising in epidemic proportions. Since known risk factors do not explain all of the variance in the population, it is important to identify novel risk factors that can lead to development of new preventive measures. Chronic psychological stress and depression are associated with type 2 diabetes but the mechanism remains unclear. Neuroendocrine changes induced by these stressors, specifically activation of the hypothalamic-pituitaryadrenal (HPA) axis and sympathetic nervous system (SNS), might provide a unifying explanation. The objectives of this review are (1) to summarize the metabolic impact of HPA axis and SNS dysfunction induced by depression and stress, (2) to summarize the relation of neuroendocrine parameters to risk factors for diabetes, (3) to discuss the limitations of assessing neuroendocrine function in populationbased and intervention studies, and (4) to summarize the evidence of the impact of stress reduction, by cognitive behavior therapy (CBT), on neuroendocrine factors and on outcomes in diabetes and obesity.
Keywords: pseudo-Cushing syndromes, Sympathetic nervous system, Cortisol Response, Major Depressive Disorder, Cognitive behavior therapy
Current Diabetes Reviews
Title: A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Volume: 3 Issue: 4
Author(s): Sherita Hill Golden
Affiliation:
Keywords: pseudo-Cushing syndromes, Sympathetic nervous system, Cortisol Response, Major Depressive Disorder, Cognitive behavior therapy
Abstract: Obesity and type 2 diabetes continue to be major public health burdens with type 2 diabetes rising in epidemic proportions. Since known risk factors do not explain all of the variance in the population, it is important to identify novel risk factors that can lead to development of new preventive measures. Chronic psychological stress and depression are associated with type 2 diabetes but the mechanism remains unclear. Neuroendocrine changes induced by these stressors, specifically activation of the hypothalamic-pituitaryadrenal (HPA) axis and sympathetic nervous system (SNS), might provide a unifying explanation. The objectives of this review are (1) to summarize the metabolic impact of HPA axis and SNS dysfunction induced by depression and stress, (2) to summarize the relation of neuroendocrine parameters to risk factors for diabetes, (3) to discuss the limitations of assessing neuroendocrine function in populationbased and intervention studies, and (4) to summarize the evidence of the impact of stress reduction, by cognitive behavior therapy (CBT), on neuroendocrine factors and on outcomes in diabetes and obesity.
Export Options
About this article
Cite this article as:
Golden Hill Sherita, A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus, Current Diabetes Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339907782330021
DOI https://dx.doi.org/10.2174/157339907782330021 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety Small Molecule-induced Beta-cell Regeneration from Alternate Cell Sources
Current Tissue Engineering (Discontinued) Mapping and Annotating Obesity-Related Genes in Pig And Human Genomes
Protein & Peptide Letters The Importance of Rhodanine Scaffold in Medicinal Chemistry: A Comprehensive Overview
Mini-Reviews in Medicinal Chemistry Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Perioperative Management of Obese Parturients
Current Women`s Health Reviews Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Evaluation of Salivary Antioxidants and Oxidative Stress Markers in Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Depression and Quality of Life in Patients with Diabetes: A Systematic Review from the European Depression in Diabetes (EDID) Research Consortium
Current Diabetes Reviews Investigating Key Genes in Type 2 Diabetes Mellitus via Combining mAP-KL and Mutual Information Network
Current Bioinformatics The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design